Rznomics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
34
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$8M
- Investors
-
18
Rznomics General Information
Description
Developer of ribonucleic acid-based gene therapies designed to create new bio drugs for cancer and intractable diseases with highly medical unmet needs. The company develops therapeutic products for the treatment of various cancers, degenerative neurological diseases, and hereditary diseases, enabling medical practitioners to treat cancerous and Alzheimer's diseases.
Contact Information
Website
www.rznomics.comCorporate Office
- 152 Jukjeon-ro, Suji-gu
- Gyeonggi-do, Dankook University Software ICT Building 327
- Yongin, Suji-gu 16890
- South Korea
Corporate Office
- 152 Jukjeon-ro, Suji-gu
- Gyeonggi-do, Dankook University Software ICT Building 327
- Yongin, Suji-gu 16890
- South Korea
Rznomics Timeline
Rznomics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. Grant | 27-Sep-2023 | $8M | Completed | Clinical Trials - Phase 1 | ||
6. Later Stage VC (Series C) | 07-Jun-2022 | Completed | Clinical Trials - Phase 1 | |||
5. Early Stage VC (Series B) | 05-Apr-2021 | Completed | Clinical Trials - Phase 1 | |||
4. Early Stage VC (Series A) | 19-Sep-2019 | Completed | Clinical Trials - Phase 1 | |||
3. Early Stage VC | 17-Jul-2018 | Completed | Clinical Trials - Phase 1 | |||
2. Accelerator/Incubator | 22-Dec-2017 | $183K | Completed | Startup | ||
1. Seed Round | 20-Dec-2017 | $183K | $183K | Completed | Startup |
Rznomics Patents
Rznomics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-4382135-A1 | Cancer-specific trans-splicing ribozyme as gene therapy product combined with radiotherapy | Pending | 06-Aug-2021 | ||
US-20230212574-A1 | Construct of self-circularization rna | Active | 10-Mar-2021 | ||
AU-2022234607-A1 | Self-circularized rna structure | Pending | 10-Mar-2021 | ||
CA-3178127-A1 | Self-circularized rna structure | Pending | 10-Mar-2021 | ||
EP-4116421-A1 | Self-circularized rna structure | Pending | 10-Mar-2021 | C12N15/67 |
Rznomics Signals
Rznomics Investors (18)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Korean government | Government | |||
AON Investment | Venture Capital | Minority | ||
IBK Capital (Korea) | Lender/Debt Provider | Minority | ||
QUAD Ventures | Venture Capital | Minority | ||
Samsung Securities | Corporation | Minority |
Rznomics FAQs
-
When was Rznomics founded?
Rznomics was founded in 2017.
-
Where is Rznomics headquartered?
Rznomics is headquartered in Yongin, South Korea.
-
What is the size of Rznomics?
Rznomics has 34 total employees.
-
What industry is Rznomics in?
Rznomics’s primary industry is Drug Discovery.
-
Is Rznomics a private or public company?
Rznomics is a Private company.
-
What is Rznomics’s current revenue?
The current revenue for Rznomics is
. -
How much funding has Rznomics raised over time?
Rznomics has raised $49.8M.
-
Who are Rznomics’s investors?
Korean government, AON Investment, IBK Capital (Korea), QUAD Ventures, and Samsung Securities are 5 of 18 investors who have invested in Rznomics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »